Myriad Genetics, Inc.

NASDAQ:MYGN

Medical - Diagnostics & Research

Healthcare
$5.53 +3.20%

+$0.14 today

Market cap
$530.45M
Beta
1.64
P/E (TTM)
-1.1
EPS (TTM)
-$4.27
52W Low $3.53High $8.59

Volume 1.26M

Average 1.81M

MYGN Operating Margin

Operating income as a percentage of revenue, showing the profitability of core operations.

Myriad Genetics, Inc.NASDAQ: MYGN

Operating Margin · Q1 FY2026 · quarter ended Mar 2026

Operating margin widens to -12.6%

Operating margin was -12.6% in Q1 FY2026, up 2.2 pp from a year earlier. On a trailing-twelve-month basis it was -46.3%, down 31.3 pp year over year. Over 3 fiscal years it widened by 12.5 pp.

Context

  • Operating margin widened in 2 of the last 3 fiscal years.
  • FY2025 was the highest level in the 4 fiscal years shown.

What to watch

Whether operating margin reaches the consensus estimate from 5 analysts of -7.7% for the fiscal year ending Dec 2026, up from -8.2% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-12.6%-9.9 pp QoQ
Last fiscal yearDec 2025
-8.2%+6.5 pp YoY
LTMMar 2026
-46.3%-31.3 pp YoY
Operating Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+2.2 pp+154.3 pp+152.1 pp
1 year+6.5 pp+0.5 pp-6.0 pp
3 years+12.5 pp-0.7 pp-13.2 pp
5 years-4.2 pp—
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Operating Margin history

Percent of revenue · from the income statement

Latest · FY2025
-8.2%
Year-over-year change
+6.5pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Operating Margin vs competitors

How MYGN compares with its peers on the latest reported figures

  • MYGN's LTM Mar 2026 operating margin of -46.3% is the 8th highest of the 10 companies compared; the peer median is -10.7%.
  • Its year-over-year change of -31.3 pp is the 8th highest of 10, against a peer median of +4.2 pp.
  • Over three fiscal years its change of +12.5 pp compares with a peer median of +28.2 pp.
MYGN Competitors Peer median
Operating Margin for MYGN and competitors
Company Period LTM level YoY 3-year change
QGENQiagen N.V.LTM Jun 202625.3% +2.4 pp+0.1 pp
VCYTVeracyte, Inc.LTM Jun 202617.0% +14.1 pp+28.2 pp
BLLNBillionToOne, Inc.LTM Jun 202610.9% +24.4 pp—
NEONeoGenomics, Inc.LTM Jun 2026-8.6% +8.1 pp+21.8 pp
NTRANatera, Inc.LTM Jun 2026-10.7% +4.2 pp+52.5 pp
FLGTFulgent Genetics, Inc.LTM Mar 2026-33.1% -8.5 pp-57.1 pp
GHGuardant Health, Inc.LTM Sep 2026-39.4% +9.6 pp+76.6 pp
MYGNMyriad Genetics, Inc.LTM Mar 2026-46.3% -31.3 pp+12.5 pp
PSNLPersonalis, Inc.LTM Mar 2026-158.9% -80.6 pp—
IMDXInsight Molecular Diagnostics Inc.LTM Mar 2026-2112.4% -588.3 pp+1124.5 pp
Peer median (excluding MYGN) -10.7%+4.2 pp+28.2 pp

Competitors are the stored peer set for MYGN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue690.6M678.4M753.2M837.6M824.5M
Cost of Revenue197.6M202M236.2M252.2M247.9M
Gross Profit493M476.4M517M585.4M576.6M
Gross Margin71.4%70.2%68.6%69.9%69.9%
Research & Development81.9M85.4M88.7M113.4M106.8M
Selling, General & Admin537.8M514.7M572.9M560M537.6M
Operating Expenses683.5M617M774.4M708.9M644.4M
Depreciation & Amortization62.8M52.7M61.9M61.2M53.7M
EBITDA12.3M(84.7M)(197.4M)(59.5M)(330.9M)
EBITDA Margin1.8%-12.5%-26.2%-7.1%-40.1%
Operating Income(190.5M)(140.6M)(257.4M)(123.5M)(67.8M)
Operating Margin-27.6%-20.7%-34.2%-14.7%-8.2%
Interest Income700K2.6M2.5M1.7M1.8M
Interest Expense6.6M3.2M2.9M2.8M10.5M
Other Income / Expenses133.4M(16.9M)(4.8M)(35.5M)(327.3M)
Income Before Tax(57.1M)(140.6M)(262.2M)(123.5M)(395.1M)
Pre-Tax Margin-8.3%-20.7%-34.8%-14.7%-47.9%
Income Tax Expense(29.9M)(28.6M)1.1M3.8M(29.2M)
Net Income(27.2M)(112M)(263.3M)(127.3M)(365.9M)
Net Margin-3.9%-16.5%-35.0%-15.2%-44.4%
EPS (Basic)(0.35)(1.39)(3.18)(1.41)(3.96)
EPS (Diluted)(0.35)(1.39)(3.18)(1.41)(3.96)
Weighted Avg Shares77.71M80.58M82.8M90.6M93.3M
Weighted Avg Shares (Diluted)78M80.6M82.8M90.6M93.3M

Myriad Genetics, Inc.

NASDAQ:MYGN

Intrinsic Alpha fair value

Locked

Current Price

$5.53

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.